Alex Azar faces skepticism regarding his ability to regulate drug prices given his past employment; Kellyanne Conway is named America's opioid czar; a study finds childhood trauma can have a generational impact.
During hearings on his nomination for HHS secretary, Alex Azar faced tough questions about how he would handle high drug costs. According to The New York Times, Azar faced distrust about claims to regulate the drug industry because of his past experience as an executive at Eli Lilly. While most Republicans viewed his experience in the drug industry as a benefit to help him understand and improve drug prices, Democrats and Senator Rand Paul, R-Kentucky, expressed skepticism due to Eli Lilly’s own past of steep drug price hikes.
In response to the continued opioid epidemic in the United States, President Donald Trump has appointed Kellyanne Conway, who is currently serving as counselor to Trump, as the country’s “opioid czar.” Whether or not Conway will focus solely on this new position, or continue to work as a counselor is unclear, reported Newsweek. Conway’s job as czar will be to “change the perception” around opioids. When Attorney General Jeff Sessions announced the appointment, he also said that all US attorney offices will designate an opioid coordinator to “determine which cases should be prosecuted at the federal level.”
Childhood trauma can have long-lasting effects and even increase the risk of serious psychiatric disorders for the daughters of women exposed to trauma. A new study tracked the health of female and male children born to children evacuated during World War II and found the female children of mothers were more likely to be hospitalized for psychiatric illness. No effects were found among male children born to the women or among children of either gender both to fathers who had been evacuated as children. The researchers postulate that traumatic events can change gene expression, which is inherited from mother to daughter.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen